GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear

Likely To Be First BCMA Approval

 
• By Andrew McConaghie

The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.

SC2007_GSK_1123492961_1200.jpg
GSK is looking to break back into the oncology market

More from Anticancer

More from Therapy Areas